Welcome to our dedicated page for Gelteq Ordinary Shares news (Ticker: GELS), a resource for investors and traders seeking the latest updates and insights on Gelteq Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gelteq Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gelteq Ordinary Shares's position in the market.
Gelteq (NASDAQ: GELS) has appointed Dr. Paul Wynne as its new Chief Scientific Officer (CSO). Dr. Wynne brings over 35 years of experience in analytical chemistry, advanced materials, drug metabolism, pharmaceutical formulation, and drug delivery. Prior to joining Gelteq, he served as Manager of the Medicines Manufacturing Innovation Centre at Monash University for eight years.
In his new role, Dr. Wynne will oversee product and formulation strategies, lead the scientific team's growth, manage the company's intellectual property portfolio, and coordinate with manufacturing partners. His expertise includes authoring over 80 peer-reviewed papers and 120 industry presentations. He holds multiple advanced degrees from RMIT University, including a PhD in Chemistry and Toxicology.
Gelteq (NASDAQ: GELS) has received FDA approval for its suitability petition for a new animal drug development, marking its entry into the animal pharmaceuticals market. The approval enables a fast-track pathway through an abbreviated new animal drug application (ANADA) for converting an existing FDA-approved generic animal drug from pill form to an oral gel form using Gelteq's ingestible gel platform.
The FDA's approval under section 512(n)(3)(C) of the FD&C Act eliminates the need for additional safety and effectiveness studies, potentially reducing the timeframe for final drug approval. However, the company notes that this suitability petition approval does not guarantee final ANADA approval for the proposed generic new animal drug.
Gelteq (NASDAQ: GELS), a company specializing in gel-based delivery solutions for various products including prescription drugs and pet care, has announced its participation in the Benchmark Company 13th Annual Discovery Investor Conference. The event will take place on December 11, 2024, at the New York Athletic Club in New York City.
Co-Founders Nathan Givoni (CEO) and Simon Szewach (Executive Chairman) will be available for one-on-one meetings with analysts and investors throughout the conference day. Interested attendees can arrange meetings through their Benchmark Company representative.
Gelteq (NASDAQ: GELS) announces that its largest U.S. customer, Healthy Extracts, has increased its initial purchase order of collagen and Mynus sugar blocker gels by 50% due to high market demand. The production is underway with shipment expected in January 2025. This expansion follows Gelteq's strategic U.S. market entry, including the recent appointment of Adam Bendell as U.S. President. The partnership aims to provide improved delivery solutions for nutraceutical products, focusing on easier digestion and better absorption.
Gelteq (NASDAQ: GELS) announces the production of 400,000 units of its gel solution in November 2024. The production run includes nutraceutical products for sports, anti-aging, and weight loss, fulfilling orders for clients in the U.S. and Australia. Delivery is expected in January 2025, with sales extending to the UAE and Asia. The company states this production milestone follows their recent IPO and demonstrates their ability to execute large-scale sales while maintaining research and development activities. Gelteq also highlights their strengthened partnership with Monash Innovation Labs to ensure quality and scalability.
Gelteq (NASDAQ: GELS) has expanded its U.S. operations by appointing Adam Bendell as President of U.S. Operations. Bendell, who brings nearly a decade of experience in corporate strategy and retail operations, has previously worked with global brands including Deloitte Consulting, Calvin Klein, Tommy Hilfiger, and Cole Haan. The appointment aligns with Gelteq's growth strategy to scale operations in the U.S. market. The company specializes in developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, and pet care products.
Gelteq has successfully completed its initial public offering (IPO), raising US$5.2 million through the sale of 1,300,000 ordinary shares at US$4.00 per share. The company's shares began trading on the Nasdaq Global Market under the symbol GELS on October 29, 2024. The Benchmark Company acted as lead managing underwriter, with a 45-day option to purchase up to 195,000 additional shares for over-allotments. Gelteq, a biotechnology company specializing in ingestible gel technology, plans to use the proceeds for manufacturing, marketing, and R&D activities.
FAQ
What is the current stock price of Gelteq Ordinary Shares (GELS)?
What is the market cap of Gelteq Ordinary Shares (GELS)?
